Neurochecklists aims to simplify neurology… by striving to be comprehensive and current. To keep a close tab on everything neurological… We sifts through tens of journals and hundreds of studies. These studies enhance neurological practice… and highlight important points. They often challenge the conventional wisdom…. and regularly dispense with redundant dogmas. So what are the groundbreaking articles… that have tackled the big issues? Which are the papers pushing […]
Neurochecklists Updates is just one year old. But it has recorded >20,000 visitors in this short time, racking up about 29,000 views! What has tickled people’s fancy in the last one year? What has caught their attention the most? Here are the most popular neurochecklists blog posts in 2017! Beach blogging. Mike Licht on Flikr. https://www.flickr.com/photos/notionscapital/2351382212 *** […]
The Neurology Lounge launched in August 2015. And it is now well into its third year. 2017 has been a busy one for the blog. It has surely been a hard slog. But with >20,000 visitors. And >30,000 post views. It’s been well worth it.
Most posts have attracted encouraging attention. But some have done so more than others.
So which were the 20 most viewed blog posts in 2017? Here is the countdown.
Join the journey; follow The Neurology Lounge in 2018.
Sodium intake and multiple sclerosis activity and progression in BENEFIT Fitzgerald KC, Munger KL, Hartung HP, et al; BENEFIT Study Group. Ann Neurol 2017; 82:20-29. Abstract OBJECTIVE: To assess whether a high-salt diet, as measured by urinary sodium concentration, is associated with faster conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) and MS […]
Polycystic kidney disease is significantly associated with dementia risk. Yu TM, Chuang YW, Sun KT, et al. Neurology 2017; 89:1457-1463. Abstract OBJECTIVE: Data on the risk of neurodegenerative diseases, including Alzheimer disease (AD) and Parkinson disease (PD), in patients with polycystic kidney disease (PKD) are lacking. METHODS: A total of 4,229 patients who were aged […]
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder which causes loss of the fatty myelin covering of large nerves (demyelination). This slows down the speed at which the nerves can transmit electrical impulses. People with CIDP develop weakness and sensory disturbances, but not always in equal measure. CIDP is a pain for the afflicted, and a veritable nightmare for the neurologist.
The diagnostic process for CIDP includes some rather uncomfortable tests such as nerve conduction studies and lumbar puncture (spinal tap). CIDP is however a most rewarding disease to treat because many people respond to immune treatments such as steroids, intravenous immunoglobulins (IVIG), or plasma exchange (PE).
The diagnosis of CIDP is however not straightforward. The results of the tests are not always clearcut, and a lot of sifting and sorting goes into nailing the diagnosis. And even when the diagnosis is eventually made, there is a very long list of potential causes of CIDP which often require treatment on their own merit. Worryingly, some of these conditions make the treatment of CIDP difficult. And this is where IgG antibodies play a nasty role in CIDP.
Neurologists are now recognising that a subset of people with CIDP have IgG4 antibodies which greatly influence the clinical presentation and the treatment of CIDP. Anti-contactin antibody is one such antibody, but by far the most important is anti-neurofascin 155 (NF155). What do we know about this antibody? How does it influence the course of CIDP? To answer these questions, below are 10 important things we now know about CIDP associated with anti-NF155.
1. Anti-NF155 is an antibody to paranodal structures 2. The antibody is present in 7-14% of people with CIDP 3. CIDP with anti-NF155 usually affects young subjects 4. Anti NF155 antibody CIDP is usually severe 5. Anti NF155 may cause central nervous system inflammation 6. It causes a very high protein level in the spinal fluid 7. It causes very severe changes on nerve conduction studies 8. It responds poorly to intravenous immunoglobulins (IVIg) 9. It may respond to steroids and plasma exchange 10. Treatment-resistant cases may respond to Rituximab
Why not check out everything CIDP on Neurochecklists:
A population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy Abbott D, Johnson NE, Cannon-Albright LA Muscle Nerve 2016; 54:783-785. Abstract Introduction: The risk of cancer in patients diagnosed with myotonic dystrophy (DM) is reported for the homogeneous Utah population. Methods: Clinical data accessed from the largest Utah healthcare providers have been […]
Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes Martinelli V, Dalla Costa G, Messina MJ, et al. Acta Neurol Scand 2017; 136:454-461. Abstract Objectives: Since its introduction, MRI had a major impact on the early and more precise diagnosis of multiple sclerosis (MS), and the 2010 diagnostic criteria even allow a […]